Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024
Global Biologics Market – Drivers, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.
The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth oppurtunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.
Market Analysis: The “Global Biologics market” is estimated to witness a CAGR of 9.9% during the forecast period 2018–2024. The global market is analyzed based on three segments – Product, Application and regions.
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.
Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.
Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.
Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.
Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received second FDA approval for Kymriah to treat patients with B-cell lymphoma.
Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.
The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth oppurtunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.
Market Analysis: The “Global Biologics market” is estimated to witness a CAGR of 9.9% during the forecast period 2018–2024. The global market is analyzed based on three segments – Product, Application and regions.
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.
Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.
Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.
Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.
Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received second FDA approval for Kymriah to treat patients with B-cell lymphoma.
Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
1.2.1 R&D pipeline in pharmaceutical industry
1.2.2 Top pharma drugs by sales in 2017 ($Million)
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Biologics patent expiration in US and Europe (2010-2020)
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the biologics market
3.5 Related Markets
3.5.1 Over the counter drugs
3.5.2 Orphan drugs
3.5.3 Human Insulin
4 MARKET OUTLOOK
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Biologics Market Dynamics
5.1.1 Drivers
5.1.1.1 Growing incidence of disease across the globe
5.1.1.2 Increasing number of biologics approvals
5.1.2 Opportunities
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials
5.1.2.2 Increasing opportunities in emerging markets
5.1.3 Restraints
5.1.3.1 Challenges associated with biologics production
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 PRODUCTS: MARKET SIZE & ANALYSIS
6.1 Overview
6.2 Monoclonal antibodies
6.3 Recombinant proteins/Hormones
6.4 Vaccines
6.5 Cell and Gene Therapy
6.6 Others
7 APPLICATIONS: MARKET SIZE & ANALYSIS
7.1 Overview
7.2 Cancer
7.3 Immunological disorders
7.4 Infectious disease
7.5 Hematologic disorders
7.6 Cardiovascular disease
7.7 Others
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 US
8.2.2 Canada
8.3 Europe
8.3.1 UK
8.3.2 Germany
8.3.3 France
8.3.4 Spain
8.4 Asia Pacific
8.4.1 India
8.4.2 China
8.4.3 Japan
8.5 Rest of the World
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 F .Hoffmann-La Roche
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategy
10.2 Sanofi S.A
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Amgen Inc
10.3.1 Overview
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategies
10.4 Novo Nordisk A/S
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 AbbVie Inc
10.5.1 Overview
10.5.2 Geographic Presence
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
10.6 Johnson & Johnson
10.6.1 Overview
10.6.2 Business Units
10.6.3 Geographic Revenue
10.6.4 Business Focus
10.6.5 SWOT Analysis
10.6.6 Business Strategies
10.7 Novartis AG
10.7.1 Overview
10.7.2 Business Units
10.7.3 Geographic Revenue
10.7.4 Business Focus
10.7.5 SWOT Analysis
10.7.6 Business Strategies
11 COMPANIES TO WATCH FOR
11.1 Bristol-Myers Squibb
11.1.1 Overview
11.2 GlaxoSmithKline plc
11.2.1 Overview
11.3 Merck & Co
11.3.1 Overview
11.4 Eli Lilly and Company Ltd
11.4.1 Overview
11.5 Teva Pharmaceutical Industries Ltd
11.5.1 Overview
11.6 AstraZeneca PLC
11.6.1 Overview
11.7 Takeda pharmaceuticals
11.7.1 Overview
Annexure
Acronyms
1.1 Industry Overview
1.2 Industry Trends
1.2.1 R&D pipeline in pharmaceutical industry
1.2.2 Top pharma drugs by sales in 2017 ($Million)
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Biologics patent expiration in US and Europe (2010-2020)
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the biologics market
3.5 Related Markets
3.5.1 Over the counter drugs
3.5.2 Orphan drugs
3.5.3 Human Insulin
4 MARKET OUTLOOK
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Biologics Market Dynamics
5.1.1 Drivers
5.1.1.1 Growing incidence of disease across the globe
5.1.1.2 Increasing number of biologics approvals
5.1.2 Opportunities
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials
5.1.2.2 Increasing opportunities in emerging markets
5.1.3 Restraints
5.1.3.1 Challenges associated with biologics production
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 PRODUCTS: MARKET SIZE & ANALYSIS
6.1 Overview
6.2 Monoclonal antibodies
6.3 Recombinant proteins/Hormones
6.4 Vaccines
6.5 Cell and Gene Therapy
6.6 Others
7 APPLICATIONS: MARKET SIZE & ANALYSIS
7.1 Overview
7.2 Cancer
7.3 Immunological disorders
7.4 Infectious disease
7.5 Hematologic disorders
7.6 Cardiovascular disease
7.7 Others
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 US
8.2.2 Canada
8.3 Europe
8.3.1 UK
8.3.2 Germany
8.3.3 France
8.3.4 Spain
8.4 Asia Pacific
8.4.1 India
8.4.2 China
8.4.3 Japan
8.5 Rest of the World
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 F .Hoffmann-La Roche
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategy
10.2 Sanofi S.A
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Amgen Inc
10.3.1 Overview
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategies
10.4 Novo Nordisk A/S
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Presence
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 AbbVie Inc
10.5.1 Overview
10.5.2 Geographic Presence
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies
10.6 Johnson & Johnson
10.6.1 Overview
10.6.2 Business Units
10.6.3 Geographic Revenue
10.6.4 Business Focus
10.6.5 SWOT Analysis
10.6.6 Business Strategies
10.7 Novartis AG
10.7.1 Overview
10.7.2 Business Units
10.7.3 Geographic Revenue
10.7.4 Business Focus
10.7.5 SWOT Analysis
10.7.6 Business Strategies
11 COMPANIES TO WATCH FOR
11.1 Bristol-Myers Squibb
11.1.1 Overview
11.2 GlaxoSmithKline plc
11.2.1 Overview
11.3 Merck & Co
11.3.1 Overview
11.4 Eli Lilly and Company Ltd
11.4.1 Overview
11.5 Teva Pharmaceutical Industries Ltd
11.5.1 Overview
11.6 AstraZeneca PLC
11.6.1 Overview
11.7 Takeda pharmaceuticals
11.7.1 Overview
Annexure
Acronyms
LIST OF TABLES
Table 1 PHARMA DRUGS BY SALES, 2017
Table 2 GLOBAL BIOLOGICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 OTHER PROMINENT VENDORS OF BIOLOGICS MARKET
Table 4 F .HOFFMANN-LA ROCHE: OFFERINGS
Table 5 F .HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 6 SANOFI.: OFFERINGS
Table 7 SANOFI: RECENT DEVELOPMENTS
Table 8 AMGEN INC.: OFFERINGS
Table 9 AMGEN INC.: RECENT DEVELOPMENTS
Table 10 NOVO NORDISK A/S: OFFERINGS
Table 11 NOVO NORDISK A/S: RECENT DEVELOPMENTS
Table 12 ABBVIE INC.: OFFERINGS
Table 13 ABBVIE INC: RECENT DEVELOPMENTS
Table 14 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 16 NOVARTIS AG: PRODUCT OFFERINGS
Table 17 NOVARTIS AG: RECENT DEVELOPMENTS
Table 18 NOVARTIS AG: OVERVIEW SNAPSHOT
Table 19 BRISTOL-MYERS SQUIBB: SNAPSHOT
Table 20 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS
Table 21 GLAXOSMITHKLINE PLC.: OVERVIEW
Table 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 23 MERCK & CO: OVERVIEW
Table 24 MERCK & CO: RECENT DEVELOPMENTS
Table 25 ELI LILLY AND COMPANY: SNAPSHOT
Table 26 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW
Table 28 TEVA PHARMACEUTICAL: RECENT DEVELOPMENTS
Table 29 ASTRAZENECA PLC: SNAPSHOT
Table 30 ASTRAZENECA PLC: RECENT DEVELOPMENTS
Table 31 TAKEDA PHARMACEUTICALS: SNAPSHOT
Table 32 TAKEDA PHARMACEUTICALS: RECENT DEVELOPMENTS
Table 1 PHARMA DRUGS BY SALES, 2017
Table 2 GLOBAL BIOLOGICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 OTHER PROMINENT VENDORS OF BIOLOGICS MARKET
Table 4 F .HOFFMANN-LA ROCHE: OFFERINGS
Table 5 F .HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 6 SANOFI.: OFFERINGS
Table 7 SANOFI: RECENT DEVELOPMENTS
Table 8 AMGEN INC.: OFFERINGS
Table 9 AMGEN INC.: RECENT DEVELOPMENTS
Table 10 NOVO NORDISK A/S: OFFERINGS
Table 11 NOVO NORDISK A/S: RECENT DEVELOPMENTS
Table 12 ABBVIE INC.: OFFERINGS
Table 13 ABBVIE INC: RECENT DEVELOPMENTS
Table 14 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 16 NOVARTIS AG: PRODUCT OFFERINGS
Table 17 NOVARTIS AG: RECENT DEVELOPMENTS
Table 18 NOVARTIS AG: OVERVIEW SNAPSHOT
Table 19 BRISTOL-MYERS SQUIBB: SNAPSHOT
Table 20 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS
Table 21 GLAXOSMITHKLINE PLC.: OVERVIEW
Table 22 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 23 MERCK & CO: OVERVIEW
Table 24 MERCK & CO: RECENT DEVELOPMENTS
Table 25 ELI LILLY AND COMPANY: SNAPSHOT
Table 26 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OVERVIEW
Table 28 TEVA PHARMACEUTICAL: RECENT DEVELOPMENTS
Table 29 ASTRAZENECA PLC: SNAPSHOT
Table 30 ASTRAZENECA PLC: RECENT DEVELOPMENTS
Table 31 TAKEDA PHARMACEUTICALS: SNAPSHOT
Table 32 TAKEDA PHARMACEUTICALS: RECENT DEVELOPMENTS
LIST OF CHARTS
Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)
Chart 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)
Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017
Chart 5 RESEARCH METHODOLOGY OF GLOBAL BIOLOGICS MARKET
Chart 6 GLOBAL BIOLOGICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 7 SEGMENTATION OF GLOBAL BIOLOGICS MARKET
Chart 8 PEST ANALYSIS OF GLOBAL BIOLOGICS MARKET
Chart 9 PORTER 5 FORCES ON GLOBAL BIOLOGICS MARKET
Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL BIOLOGICS MARKET
Chart 11 KEY STAKEHOLDERS
Chart 12 GLOBAL BIOLOGICS BY PRODUCT SEGMENTATION, 2017 (%)
Chart 13 GLOBAL MONOCLONAL ANTOBODY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 14 GLOBAL RECOMBINANT PROTEIN/HORMONES MARKET FORECAST, 2017–2024 ($MILLION)
Chart 15 GLOBAL VACCINES MARKET FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 17 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 18 GLOBAL BIOLOGICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 19 GLOBAL BIOLOGICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 20 BIOLOGICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 21 BIOLOGICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 22 BIOLOGICS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION)
Chart 23 BIOLOGICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 24 F .HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 25 F .HOFFMANN.LA ROCHE: BUSINESS UNITS
Chart 26 F .HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 27 F .HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 28 SANOFI: OVERVIEW SNAPSHOT
Chart 29 SANOFI SA: BUSINESS UNITS
Chart 30 SANOFI SA: GEOGRAPHIC PRESENCE
Chart 31 SANOFI SA: SWOT ANALYSIS
Chart 32 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 33 AMGEN INC.: GEOGRAPHIC PRESENCE
Chart 34 AMGEN INC: SWOT ANALYSIS
Chart 35 NOVO NORDISK: OVERVIEW SNAPSHOT
Chart 36 NOVO NORDISK: BUSINESS UNITS
Chart 37 NOVO NORDISK: GEOGRAPHIC PRESENCE
Chart 38 NOVO NORDISK A/S: SWOT ANALYSIS
Chart 39 ABBVIEE INC: OVERVIEW SNAPSHOT
Chart 40 ABBVIEE INC.: GEOGRAPHIC PRESENCE
Chart 41 ABBVIE INC.: SWOT ANALYSIS
Chart 42 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 43 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 44 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 45 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 46 NOVARTIS AG: BUSINESS UNITS
Chart 47 NOVARTIS AG: GEOGRAPHIC REVENUE
Chart 48 NOVARTIS AG: SWOT ANALYSIS
Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)
Chart 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)
Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017
Chart 5 RESEARCH METHODOLOGY OF GLOBAL BIOLOGICS MARKET
Chart 6 GLOBAL BIOLOGICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 7 SEGMENTATION OF GLOBAL BIOLOGICS MARKET
Chart 8 PEST ANALYSIS OF GLOBAL BIOLOGICS MARKET
Chart 9 PORTER 5 FORCES ON GLOBAL BIOLOGICS MARKET
Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL BIOLOGICS MARKET
Chart 11 KEY STAKEHOLDERS
Chart 12 GLOBAL BIOLOGICS BY PRODUCT SEGMENTATION, 2017 (%)
Chart 13 GLOBAL MONOCLONAL ANTOBODY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 14 GLOBAL RECOMBINANT PROTEIN/HORMONES MARKET FORECAST, 2017–2024 ($MILLION)
Chart 15 GLOBAL VACCINES MARKET FORECAST, 2017–2024 ($MILLION)
Chart 16 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 17 GLOBAL CELL AND GENE THERAPY MARKET FORECAST, 2017–2024 ($MILLION)
Chart 18 GLOBAL BIOLOGICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 19 GLOBAL BIOLOGICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 20 BIOLOGICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 21 BIOLOGICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 22 BIOLOGICS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION)
Chart 23 BIOLOGICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 24 F .HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 25 F .HOFFMANN.LA ROCHE: BUSINESS UNITS
Chart 26 F .HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 27 F .HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 28 SANOFI: OVERVIEW SNAPSHOT
Chart 29 SANOFI SA: BUSINESS UNITS
Chart 30 SANOFI SA: GEOGRAPHIC PRESENCE
Chart 31 SANOFI SA: SWOT ANALYSIS
Chart 32 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 33 AMGEN INC.: GEOGRAPHIC PRESENCE
Chart 34 AMGEN INC: SWOT ANALYSIS
Chart 35 NOVO NORDISK: OVERVIEW SNAPSHOT
Chart 36 NOVO NORDISK: BUSINESS UNITS
Chart 37 NOVO NORDISK: GEOGRAPHIC PRESENCE
Chart 38 NOVO NORDISK A/S: SWOT ANALYSIS
Chart 39 ABBVIEE INC: OVERVIEW SNAPSHOT
Chart 40 ABBVIEE INC.: GEOGRAPHIC PRESENCE
Chart 41 ABBVIE INC.: SWOT ANALYSIS
Chart 42 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 43 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 44 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 45 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 46 NOVARTIS AG: BUSINESS UNITS
Chart 47 NOVARTIS AG: GEOGRAPHIC REVENUE
Chart 48 NOVARTIS AG: SWOT ANALYSIS
